TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
miscellaneous
systematic review
meta-analysis
network meta-analysis
Select
angiotensin-receptor blockers
mechanisms (all)
angiotensin renin system blockade
angiotensin-receptor blockers
All type of patient
patient types (all)
All type of patient
angiotensin receptor blocker
endopeptidase inhibitors
classes (all)
angiotensin receptor blocker
endopeptidase inhibitors
ramipril
irbesartan
losartan
telmisartan
candesartan
olmesartan
treatments (all)
Angiotensin-Converting Enzyme Inhibitors
ramipril
angiotensin II receptor antagonist
irbesartan
losartan
telmisartan
angiotensin II receptor antagonist
candesartan
olmesartan
vs placebo or control
vs angiotensin-converting enzyme inhibitors
vs beta-blockers
vs calcium blockers
vs calcium-channel blockers
vs diuretics
comparators (all)
vs placebo or control
vs angiotensin-converting enzyme inhibitors
vs beta-blockers
vs calcium blockers
vs calcium-channel blockers
vs diuretics
tags (all)
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
All cause death (25)
Cardiovascular death (22)
stroke (fatal and non fatal) (21)
myocardial infarction (fatal and non fatal) (18)
Heart failure (15)
cardiovascular events (13)
Coronary event (9)
Diabetes onset (8)
Cancer (5)
Revascularization (4)
Adverse events leading to treatment discontinuation (4)
Cough (4)
angiodema (4)
Hypotension (4)
cardiac death (2)
lung cancer (2)
Non fatal stroke (2)
Non fatal MI (2)
cancer related death (1)
cardiovascular death, MI, stroke (1)
hypertension (1)
Serious adverse event (1)
macrovascular events (1)
2 endpoints selected
All cause death (25)
Cardiovascular death (22)
stroke (fatal and non fatal) (21)
myocardial infarction (fatal and non fatal) (18)
Heart failure (15)
cardiovascular events (13)
Coronary event (9)
Diabetes onset (8)
Cancer (5)
Revascularization (4)
Adverse events leading to treatment discontinuation (4)
Cough (4)
angiodema (4)
Hypotension (4)
cardiac death (2)
lung cancer (2)
Non fatal stroke (2)
Non fatal MI (2)
cancer related death (1)
cardiovascular death, MI, stroke (1)
hypertension (1)
Serious adverse event (1)
macrovascular events (1)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
All cause death
Cardiovascular death
angiotensin-receptor blockers
not classified
Suzuki, 2008
ARBs
control
Risk of bias
negative
-34%
-40%
Ruilope, 2010
LCZ696
placebo
Low risk of bias
-
IDNT (irbesartan vs amlodipine), 2001
irbesartan
amlodipine
Low risk of bias
negative
3%
38%
VALUE, 2004
NCT
valsartan
amlodipine
Low risk of bias
suggesting
2%
-1%
DETAIL, 2004
telmisartan
enalapril
Low risk of bias
negative
8%
63%
OSCAR, 2011
NCT
olmesartan 40 mg
olmesartan 20 mg plus a calcium-channel blocker
Risk of bias
negative
candesartan
Takahashi, 2006
candesartan
control
Exploratory
negative
-100%
E-COST, 2005
candesartan
conventional treatment
Risk of bias
suggesting
-6%
∞%
E-COST-R, 2005
candesartan
conventional treatment
Risk of bias
negative
4%
4%
HIJ-CREATE, 2009
candesartan
conventional treatment
Risk of bias
suggesting
17%
12%
SCOPE, 2003
candesartan
placebo
Low risk of bias
negative
-3%
-5%
TROPHY, 2006
NCT
candesartan
placebo
Low risk of bias
suggesting
CASE-J, 2008
candesartan
amlodipine
Risk of bias
suggesting
-15%
ALPINE, 2003
candesartan
hydrochlorothiazide
Low risk of bias
suggesting
irbesartan
IDNT (irbesartan vs pbo), 2001
irbesartan
placebo
Low risk of bias
negative
-8%
11%
IRMA 2, 2001
irbesartan
placebo
Low risk of bias
negative
13%
losartan
RENAAL, 2001
losartan
placebo
Low risk of bias
-
LIFE, 2002
losartan
atenolol
Low risk of bias
suggesting
-11%
-13%
olmesartan
ROADMAP, 2010
NCT
olmesartan
placebo
Low risk of bias
suggesting
72%
396%
ORIENT
NCT
olmesartan
placebo
Low risk of bias
negative
-4%
236%
ramipril
ONTARGET (association vs ramipril), 2008
NCT
telmisartan + ramipril
ramipril
Low risk of bias
negative
6%
4%
ONTARGET (association vs telmisartan), 2008
NCT
telmisartan + ramipril
telmisartan
Low risk of bias
suggesting
8%
4%
telmisartan
TRANSCEND, 2008
NCT
telmisartan
placebo
Low risk of bias
suggesting
5%
2%
PROPHESS, 2008
NCT
telmisartan
placebo
Low risk of bias
negative
2%
-15%
ONTARGET (telmisartan alone), 2008
NCT
telmisartan
ramipril
Low risk of bias
suggesting
-2%
0%
×
Modal title